Cowen & Co. analyst Boris Peaker maintained a Hold rating on Emergent Biosolutions (EBS) today and set a price target of $64. The company’s shares closed yesterday at $69.70, close to its 52-week high of $71.77.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.4% and a 42.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $71.80 average price target.
See today’s analyst top recommended stocks >>
Based on Emergent Biosolutions’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $20.95 million. In comparison, last year the company had a net profit of $33.55 million.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.
